Belpointe Asset Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Belpointe Asset Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-67,567	Closed	-$16.7K	–	1222
2026 Q1	$16.7K	Buy	+67,567	New	+$26.9K	﹤0.01%	1062
2023 Q2	–	Sell	-1,000	Closed	-$1.76K	–	2884
2023 Q1	$1.76K	Hold	1,000	–	–	﹤0.01%	3334
2022 Q4	$3.14K	Buy	+1,000	New	+$3.88K	﹤0.01%	3098

Other funds holding SGMO

AIM

Axiom Investment Management New York $150M AUM

HIG

Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Belpointe Asset Management's SGMO Position: Q2 2026 in Review

Belpointe Asset Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 67,567 shares — an estimated $16.7K sold.

Belpointe Asset Management first reported a position in SGMO in Q4 2022 and held it in 3 quarters. The position peaked at $16.7K in Q1 2026. 2 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

Belpointe Asset Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
Belpointe Asset Management sold 67,567 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $16.7K.
Belpointe Asset Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2022 and held it in 3 quarters.
Belpointe Asset Management's SANGAMO THERAPEUTICS INC position peaked at $16.7K in Q1 2026.
2 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.